HIV-derived vectors for therapy and vaccination against HIV. (Q37985328)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

title

HIV-derived vectors for therapy and vaccination against HIV (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

Nathalie Arhel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

Sébastien Nisole

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

Anne-Sophie Beignon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

author name string

F Di Nunzio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

P Charneau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

13 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

2499-2509

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22342915 AND SRC:MED&resulttype=core&format=json

Pathogenic Mechanisms of HIV Disease

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The dynamics of CD4 T-cell depletion in HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV/AIDS epidemiology, pathogenesis, prevention, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1 genome nuclear import is mediated by a central DNA flap

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Stable gene transfer to the nervous system using a non-primate lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Vectors derived from simian immunodeficiency virus (SIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-2 and SIV vector systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

FIV: from lentivirus to lentivector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Enhanced transgene expression in cord blood CD34( )-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The use of cell-delivered gene therapy for the treatment of HIV/AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Stem cell-based anti-HIV gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory act

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Transduction of SIV-Specific TCR Genes into Rhesus Macaque CD8 T Cells Conveys the Ability to Suppress SIV Replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Gene transfer in humans using a conditionally replicating lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Activation of Immature Monocyte-Derived Dendritic Cells After Transduction with High Doses of Lentiviral Vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8( ) T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Skin-derived dendritic cells induce potent CD8( ) T cell immunity in recombinant lentivector-mediated genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The role of skin-derived dendritic cells in CD8 T cell priming following immunization with lentivectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

DC-virus interplay: a double edged sword

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8 T-cell responses after immunization with recombinant lentivector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Effect of CD8 lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Possible applications for replicating HIV 1 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV vaccine design: insights from live attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Pseudotyped single-cycle simian immunodeficiency viruses expressing gamma interferon augment T-cell priming responses in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Development and characterization of a new single cycle vaccine vector in the simian immunodeficiency virus model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP ) mimicking naturally occurring HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Induction of immunity to human immunodeficiency virus type-1 by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A lentiviral vector pseudotype suitable for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Large-scale production means for the manufacturing of lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4 CD25 regulatory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Targeting dendritic cell signaling to regulate the response to immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8 T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Engineered lentivector targeting of dendritic cells for in vivo immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8 and CD4 T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Use of human MAR elements to improve retroviral vector production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Influence of insulators on transgene expression from integrating and non-integrating lentiviral vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The role of unintegrated DNA in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Novel integrase-defective lentiviral episomal vectors for gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Integrase-defective lentiviral vectors: progress and applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Effective gene therapy with nonintegrating lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Protective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

TRIM family proteins: retroviral restriction and antiviral defence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Human immunodeficiency virus, restriction factors, and interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Host restriction factors blocking retroviral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Generation of simian-tropic HIV-1 by restriction factor evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

A macaque model of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Lack of endogenous TRIM5 -mediated restriction in rhesus macaque dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Independent evolution of an antiviral TRIMCyp in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Evolution of a TRIM5-CypA splice isoform in old world monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089

Host factors influencing susceptibility to HIV infection and AIDS progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.01.089